Recruiting
Phase 3

PF-08634404 with Pembrolizumab

Sponsor:

Pfizer

Code:

NCT07222566

Conditions

Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung (NSCLC)

Metastatic Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PF-08634404

Pembrolizumab

Chemotherapy Regimen 1

Chemotherapy Regimen 2

Study Details

Brief summary:

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

  • Be 18 years or older.
  • Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC.
  • Is not a candidate for complete surgical resection or curative chemoradiotherapy.
  • Do not have known actionable genomic alterations
  • Be treatment naïve for advanced or metastatic disease

Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2.

Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion:

  • Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor.
  • Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor.

Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects.

The study will include regular visits for:

  • Treatment and health checks: while participant continues receiving treatment.
  • Tests to monitor how cancer responds: every 6 weeks during the first 48 weeks, then every 12 weeks thereafter.

Conditions

Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung (NSCLC)

Metastatic Non Small Cell Lung Cancer

Study ID

NCT07222566

Start date

Jan 6, 2026

Status verified date

Aug, 2026

Completion date

Aug 26, 2032

Anticipated

Primary completion date

Feb 27, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years of age or older at screening.
  • Have pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV)squamous or non-squamous NSCLC and not be a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer Tumor, lymph nodes, metastasis (TNM) staging system).
  • Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy
  • PD-L1 status available based on local testing results
  • Measurable disease based on RECIST v1.1 per investigator.
  • Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1
  • Expected survival ≥12 weeks

Exclusion Criteria:

  • Participants with known actionable genomic alteration (AGAs), including estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), Repressor of Silencing 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), rearranged during transfection (RET), and mesenchymal-epithelial transition (MET), for which there are available first-line therapies per local standard-of-care (SOC) are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology.
  • Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter < 1 cm are permitted.
  • Participants with clinically significant risk of hemorrhage or fistula are excluded.
  • Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
  • Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1.
  • Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody.
  • History of allogeneic organ / hematopoietic stem cell transplantation.
  • Participants with any of the following respiratory conditions:
  • Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis
  • Grade ≥3 pulmonary disease unrelated to underlying malignancy
  • History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial/severe venous thromboembolic events.
  • Major surgery < 4 weeks or minor surgery < 3 days prior to first dose of study intervention.
  • History of severe bleeding tendency or coagulation dysfunction
  • History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose.
  • Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV).
  • Participants with history of immunodeficiency
  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.
  • Previous systemic anti-tumor therapy including:

1. Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC.
2. Previous treatment with immunotherapy
3. Prior radiotherapy > 30 Gy to the lung < 6 months of first dose of study intervention
4. Palliative local therapy < 2 weeks before the first dose of study intervention;
5. Non-specific immunomodulatory therapy < 2 weeks before the first dose.
6. Prior systemic anti-angiogenic therapy
  • Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, adverse events from prior immunotherapy not improved to Grade 1 before screening, or required treatment with systemic immunosuppressive therapy.
  • Prior and concomitant therapy:

1. therapeutic oral or parenteral anticoagulants or thrombolytic agents < 10 days to the first dose.
2. chronic antiplatelet therapy <7 days to randomization.
3. live or attenuated live vaccine < 4 weeks to the first dose.
4. current high-dose systemic corticosteroids.
5. prohibited concomitant medication(s) < 21 days to the first dose.
  • Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.

Study Design

Enrollment

1410 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm A

Participants will receive PF-08634404 combined with chemotherapy regimen 1, followed by maintenance therapy with PF-08634404.

active comparator: Arm B

Participants will receive pembrolizumab combined with chemotherapy regimen 1, followed by maintenance therapy with pembrolizumab.

experimental: Arm C

Participants will receive PF-08634404 combined with chemotherapy regimen 2, followed by maintenance therapy with PF-08634404 and chemotherapy.

active comparator: Arm D

Participants will receive pembrolizumab combined with chemotherapy regimen 2, followed by maintenance therapy with pembrolizumab and chemotherapy.

Interventions

PF-08634404

Solution for infusion

Pembrolizumab

Injection for IV use

Chemotherapy Regimen 1

Injection for IV use

Chemotherapy Regimen 2

Injection for IV use

Primary outcome measure

  • Overall Survival [ Time Frame: Approximately 39 months ]
  • Progression Free Survival (PFS) assessed by blinded independent central review (BICR) [ Time Frame: Approximately 32 months ]

Central Contacts and Locations

Central contacts

Pfizer CT.gov Call Center

1-800-718-1021ClinicalTrials.gov_Inquiries@pfizer.com

Locations

Pioneer Research Center

Recruiting

Bullhead City, Arizona, United States, 86442

Ironwood Cancer & Research Centers

Recruiting

Chandler, Arizona, United States, 85224

Ironwood Cancer & Research Centers

Recruiting

Gilbert, Arizona, United States, 85297

Ironwood Cancer & Research Centers

Recruiting

Glendale, Arizona, United States, 85306

Ironwood Cancer & Research Centers

Recruiting

Goodyear, Arizona, United States, 85395

Ironwood Cancer & Research Centers

Recruiting

Mesa, Arizona, United States, 85202

Ironwood Cancer & Research Centers

Recruiting

Mesa, Arizona, United States, 85206

Ironwood Cancer & Research Centers

Recruiting

Phoenix, Arizona, United States, 85028

Ironwood Cancer & Research Centers

Recruiting

Scottsdale, Arizona, United States, 85260

Highlands Oncology Group

Recruiting

Fayetteville, Arkansas, United States, 72703

Highlands Oncology Group

Recruiting

Rogers, Arkansas, United States, 72758

Highlands Oncology Group

Recruiting

Springdale, Arkansas, United States, 72762

Oncura Health - Anaheim

Recruiting

Anaheim, California, United States, 92805

Memorial Care Orange Coast Medical Center Attn

Recruiting

Fountain Valley, California, United States, 92708

MemorialCare Orange Coast Medical Center

Recruiting

Fountain Valley, California, United States, 92708

OC Blood and Cancer Care

Recruiting

Fountain Valley, California, United States, 92708

Oncura Health - Fountain Valley

Recruiting

Fountain Valley, California, United States, 92708

Oncura Health - Corporate (Central IDS & Regulatory Only)

Recruiting

Glendale, California, United States, 91204

Memorial Care Saddleback Medical Center Attn

Recruiting

Laguna Hills, California, United States, 92653

MemorialCare Saddleback Medical Center

Recruiting

Laguna Hills, California, United States, 92653

Stockton Hematology Oncology Medical Group

Recruiting

Lodi, California, United States, 95242

Memorial Care Long Beach Medical Center

Recruiting

Long Beach, California, United States, 90806

Oncura Health - Good Samaritan

Recruiting

Los Angeles, California, United States, 90017

Stockton Hematology Oncology Medical Group

Recruiting

Manteca, California, United States, 95336

Stockton Hematology Oncology Medical Group

Recruiting

Modesto, California, United States, 95350

Oncura Health - Riverside

Recruiting

Riverside, California, United States, 92501

Sansum Clinic

Recruiting

Santa Barbara, California, United States, 93105

Sansum Clinic

Recruiting

Solvang, California, United States, 93463

Stockton Hematology Oncology Group

Recruiting

Stockton, California, United States, 95204

Stockton Hematology Oncology Medical Group

Recruiting

Tracy, California, United States, 95377

Oncura Health - Valley Presbyterian

Recruiting

Van Nuys, California, United States, 91405

Florida Cancer Specialists

Recruiting

Bonita Springs, Florida, United States, 34135

Florida Cancer Specialists

Recruiting

Bradenton, Florida, United States, 34211

Florida Cancer Specialists

Recruiting

Cape Coral, Florida, United States, 33909

Florida Cancer Specialists

Recruiting

Clearwater, Florida, United States, 33761

BRCR Global- Coral Springs

Recruiting

Coral Springs, Florida, United States, 33065

Florida Cancer Specialists

Recruiting

Daytona Beach, Florida, United States, 32117

Cancer Specialists of North Florida

Recruiting

Fleming Island, Florida, United States, 32003

Florida Cancer Specialists

Recruiting

Fleming Island, Florida, United States, 32003

Helios Clinical Research

Recruiting

Fort Lauderdale, Florida, United States, 33316

Florida Cancer Specialists - South

Recruiting

Fort Myers, Florida, United States, 33901

Florida Cancer Specialists

Recruiting

Fort Myers, Florida, United States, 33905

Florida Cancer Specialists

Recruiting

Fort Myers, Florida, United States, 33908

Florida Cancer Specialists

Recruiting

Gainesville, Florida, United States, 32605

Cancer Specialists of North Florida

Recruiting

Jacksonville, Florida, United States, 32204

Cancer Specialists of North Florida

Recruiting

Jacksonville, Florida, United States, 32218

Cancer Specialists of North Florida

Recruiting

Jacksonville, Florida, United States, 32256

Cancer Specialists of North Florida

Recruiting

Jacksonville, Florida, United States, 32258

Florida Cancer Specialists

Recruiting

Largo, Florida, United States, 33770

Florida Cancer Specialists

Recruiting

Lecanto, Florida, United States, 34461

Florida Cancer Specialists

Recruiting

N. Venice, Florida, United States, 34275

Florida Cancer Specialists

Recruiting

Naples, Florida, United States, 34102

Cancer Specialists of North Florida

Recruiting

Neptune Beach, Florida, United States, 32266

Florida Cancer Specialists

Recruiting

Ocala, Florida, United States, 34474

Alpha Clinical Research Centers LLC

Recruiting

Orange City, Florida, United States, 32763

Florida Cancer Specialists

Recruiting

Orange City, Florida, United States, 32763

Mid Florida Hematology and Oncology Center

Recruiting

Orange City, Florida, United States, 32763

Florida Cancer Specialists

Recruiting

Orlando, Florida, United States, 32806

Orlando Health Ambulatory Care Center

Recruiting

Orlando, Florida, United States, 32806

Orlando Health Cancer Institute

Recruiting

Orlando, Florida, United States, 32806

Orlando Health Orlando Regional Medical Center

Recruiting

Orlando, Florida, United States, 32806

Cancer Care Centers of Brevard, Inc.

Recruiting

Palm Bay, Florida, United States, 32901

Florida Cancer Specialists

Recruiting

Palm Beach Gardens, Florida, United States, 33410

Florida Cancer Specialists

Recruiting

Port Charlotte, Florida, United States, 33980

Hematology Oncology Associates of the Treasure Coast

Recruiting

Port Saint Lucie, Florida, United States, 34952

Cancer Specialists of North Florida

Recruiting

Saint Augustine, Florida, United States, 32086

Florida Cancer Specialists

Recruiting

Sarasota, Florida, United States, 34236

Florida Cancer Specialists

Recruiting

Sebring, Florida, United States, 33870

Florida Cancer Specialists

Recruiting

St. Petersburg, Florida, United States, 33701

Florida Cancer Specialists

Recruiting

St. Petersburg, Florida, United States, 33705

Florida Cancer Specialists

Recruiting

Tallahassee, Florida, United States, 32308

BRCR Medical Center Inc.

Recruiting

Tamarac, Florida, United States, 33321

Florida Cancer Specialists

Recruiting

Tampa, Florida, United States, 33607

Florida Cancer Specialists

Recruiting

Tavares, Florida, United States, 32778

Florida Cancer Specialists

Recruiting

The Villages, Florida, United States, 32159

Florida Cancer Specialists

Recruiting

Trinity, Florida, United States, 34655

Florida Cancer Specialists

Recruiting

Wellington, Florida, United States, 33414

Florida Cancer Specialists - East

Recruiting

West Palm Beach, Florida, United States, 33401

Florida Cancer Specialists

Recruiting

Winter Park, Florida, United States, 32789

Illinois CancerCare - Bloomington

Recruiting

Bloomington, Illinois, United States, 61704

University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)

Recruiting

Chicago, Illinois, United States, 60612

University of Illinois Hospital and Health Sciences System

Recruiting

Chicago, Illinois, United States, 60612

Illinois Cancer Specialists

Recruiting

Chicago, Illinois, United States, 60631

Illinois CancerCare - Galesburg

Recruiting

Galesburg, Illinois, United States, 61401

Hope and Healing Cancer Services

Recruiting

Hinsdale, Illinois, United States, 60521

Hope and Healing Cancer Services

Recruiting

New Lenox, Illinois, United States, 60451

Illinois Cancer Specialists

Recruiting

Niles, Illinois, United States, 60714

Illinois CancerCare-Ottawa-Fox River Cancer Center

Recruiting

Ottawa, Illinois, United States, 61350

Illinois CancerCare-Pekin

Recruiting

Pekin, Illinois, United States, 61554

Illinois CancerCare, P.C.

Recruiting

Peoria, Illinois, United States, 61615

Illinois CancerCare-Peru - Valley Regional Cancer Center

Recruiting

Peru, Illinois, United States, 61354

Illinois CancerCare-Washington

Recruiting

Washington, Illinois, United States, 61571

Pontchartrain Cancer Center

Recruiting

Covington, Louisiana, United States, 70433

Pontchartrain Cancer Center

Recruiting

Hammond, Louisiana, United States, 70403

Maryland Oncology Hematology, P.A.

Recruiting

Annapolis, Maryland, United States, 21401

Maryland Oncology Hematology, P.A.

Recruiting

Bethesda, Maryland, United States, 20817

Maryland Oncology Hematology, P.A.

Recruiting

Brandywine, Maryland, United States, 20613

Maryland Oncology Hematology - Columbia

Recruiting

Columbia, Maryland, United States, 21044

Maryland Oncology Hematology, P.A.

Recruiting

Germantown, Maryland, United States, 20876

Maryland Oncology Hematology, P.A.

Recruiting

Largo, Maryland, United States, 20774

Maryland Oncology Hematology, P.A.

Recruiting

Rockville, Maryland, United States, 20850

Maryland Oncology Hematology, P.A.

Recruiting

Silver Spring, Maryland, United States, 20904

Minnesota Oncology Hematology, P.A.

Recruiting

Burnsville, Minnesota, United States, 55337

Minnesota Oncology Hematology, P.A.

Recruiting

Chaska, Minnesota, United States, 55318

Allina Health Cancer Institute - Mercy Hospital

Recruiting

Coon Rapids, Minnesota, United States, 55433

Minnesota Oncology Hematology, P.A.

Recruiting

Coon Rapids, Minnesota, United States, 55433

Minnesota Oncology Hematology, P.A.

Recruiting

Edina, Minnesota, United States, 55435

Minnesota Oncology Hematology, P.A.

Recruiting

Maple Grove, Minnesota, United States, 55369

Minnesota Oncology Hematology, P.A.

Recruiting

Maplewood, Minnesota, United States, 55109

Allina Health Cancer Institute - Abbott Northwestern Hospital

Recruiting

Minneapolis, Minnesota, United States, 55407

Allina Health Cancer Institute - United Hospital

Recruiting

Saint Paul, Minnesota, United States, 55102

Minnesota Oncology Hematology, P.A.

Recruiting

Woodbury, Minnesota, United States, 55125

Hattiesburg Clinic Hematology/Oncology

Recruiting

Hattiesburg, Mississippi, United States, 39401

NHO Revive Research Institute, LLC

Recruiting

Lincoln, Nebraska, United States, 68506

NHO Support Center

Recruiting

Lincoln, Nebraska, United States, 68506

Cancer Partners of Nebraska

Recruiting

Lincoln, Nebraska, United States, 68516

New York Oncology Hematology

Recruiting

Albany, New York, United States, 12206

New York Oncology Hematology

Recruiting

Clifton Park, New York, United States, 12065

Hematology Oncology Associates of Rockland

Recruiting

Nyack, New York, United States, 10960

FirstHealth Cancer Center

Recruiting

Pinehurst, North Carolina, United States, 28374

FirstHealth Moore Regional Hospital

Recruiting

Pinehurst, North Carolina, United States, 28374

Carolina Cancer Research Center

Recruiting

Wilson, North Carolina, United States, 27893

Aultman Hospital

Recruiting

Canton, Ohio, United States, 44710

Aultman Medical Group Hematology and Oncology

Recruiting

Canton, Ohio, United States, 44710

Oncology Hematology Care Clinical Trials

Recruiting

Cincinnati, Ohio, United States, 45211

Oncology Hematology Care Clinical Trials

Recruiting

Cincinnati, Ohio, United States, 45242

Oncology Hematology Care Clinical Trials

Recruiting

Cincinnati, Ohio, United States, 45245

University Hospitals Cleveland Medical Center

Recruiting

Cleveland, Ohio, United States, 44106

Oncology Hematology Care Clinical Trials

Recruiting

Fairfield, Ohio, United States, 45014

Aultman Massillon

Recruiting

Massillon, Ohio, United States, 44646

Aultman North

Recruiting

North Canton, Ohio, United States, 44720

Aultman Orrville Hospital

Recruiting

Orrville, Ohio, United States, 44667

Northwest Cancer Specialists, P.C

Recruiting

Happy Valley, Oregon, United States, 97015

Northwest Cancer Specialists, P.C.

Recruiting

Portland, Oregon, United States, 97227

Northwest Cancer Specialists, P.C

Recruiting

Tigard, Oregon, United States, 97223

Tennessee Oncology, PLLC - Chattanooga Downtown

Recruiting

Chattanooga, Tennessee, United States, 37403

Tennessee Oncology, PLLC - Chattanooga - Medical Park II

Recruiting

Chattanooga, Tennessee, United States, 37404

Tennessee Oncology, PLLC - Franklin

Recruiting

Franklin, Tennessee, United States, 37067

Tennessee Oncology, PLLC - Gallatin

Recruiting

Gallatin, Tennessee, United States, 37066

Tennessee Cancer Specialists Dowell Springs location

Recruiting

Knoxville, Tennessee, United States, 37909

University of Tennessee Medical Center

Recruiting

Knoxville, Tennessee, United States, 37920

Tennessee Cancer Specialists - Parkwest Location

Recruiting

Knoxville, Tennessee, United States, 37932

Tennessee Oncology, PLLC - Lebanon

Recruiting

Lebanon, Tennessee, United States, 37090

Tennesseee Oncology, PLLC - Mount Juliet

Recruiting

Mount Juliet, Tennessee, United States, 37122

Tennessee Oncology, PLLC - Murfreesboro

Recruiting

Murfreesboro, Tennessee, United States, 37129

SCRI Oncology Partners

Recruiting

Nashville, Tennessee, United States, 37203

Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology

Recruiting

Nashville, Tennessee, United States, 37203

Tennessee Oncology, PLLC - Saint Thomas West

Recruiting

Nashville, Tennessee, United States, 37205

Tennessee Oncology, PLLC -Shelbyville

Recruiting

Shelbyville, Tennessee, United States, 37160

Texas Oncology - West Texas

Recruiting

Abilene, Texas, United States, 79606

Texas Oncology - Northeast Texas

Recruiting

Allen, Texas, United States, 75013

Texas Oncology - West Texas

Recruiting

Amarillo, Texas, United States, 79124

Texas Oncology - DFW

Recruiting

Arlington, Texas, United States, 76012

Texas Oncology - DFW

Recruiting

Arlington, Texas, United States, 76014

Texas Oncology - Central/South Texas

Recruiting

Austin, Texas, United States, 78758

Texas Oncology - Gulf Coast

Recruiting

Beaumont, Texas, United States, 77702

Texas Oncology - DFW

Recruiting

Bedford, Texas, United States, 76022

Texas Oncology - DFW

Recruiting

Dallas, Texas, United States, 75203

Texas Oncology - DFW

Recruiting

Dallas, Texas, United States, 75230

Texas Oncology - DFW

Recruiting

Dallas, Texas, United States, 75231

Texas Oncology - DFW

Recruiting

Dallas, Texas, United States, 75237

Texas Oncology - DFW

Recruiting

Dallas, Texas, United States, 75246

Texas Oncology - Northeast Texas

Recruiting

Denison, Texas, United States, 75020

Texas Oncology - Northeast Texas

Recruiting

Denton, Texas, United States, 76201

Texas Oncology - West Texas

Recruiting

El Paso, Texas, United States, 79902

Texas Oncology - West Texas

Recruiting

El Paso, Texas, United States, 79915

Texas Oncology - West Texas

Recruiting

El Paso, Texas, United States, 79938

Texas Oncology - Northeast Texas

Recruiting

Flower Mound, Texas, United States, 75028

Texas Oncology - DFW

Recruiting

Fort Worth, Texas, United States, 76104

Texas Oncology - DFW

Recruiting

Grapevine, Texas, United States, 76051

Texas Oncology - Central/South Texas

Recruiting

Harlingen, Texas, United States, 78550

Texas Oncology - Gulf Coast

Recruiting

Houston, Texas, United States, 77024

Texas Oncology - Gulf Coast

Recruiting

Houston, Texas, United States, 77054

Texas Oncology - Gulf Coast

Recruiting

Houston, Texas, United States, 77070

Texas Oncology - Gulf Coast

Recruiting

Humble, Texas, United States, 77338

US Oncology Investigational Products Center (IPC)

Recruiting

Irving, Texas, United States, 75063

US Oncology Investigational Products Center

Recruiting

Irving, Texas, United States, 75063

Texas Oncology - Northeast Texas

Recruiting

Lewisville, Texas, United States, 75056

Texas Oncology - Northeast Texas

Recruiting

Longview, Texas, United States, 75601

Texas Oncology - Central/South Texas

Recruiting

McAllen, Texas, United States, 78503

Texas Oncology - Northeast Texas

Recruiting

McKinney, Texas, United States, 75071

Texas Oncology - West Texas

Recruiting

Midland, Texas, United States, 79701

Texas Oncology - West Texas

Recruiting

Odessa, Texas, United States, 79761

Texas Oncology - Northeast Texas

Recruiting

Palestine, Texas, United States, 75801

Texas Oncology - Northeast Texas

Recruiting

Paris, Texas, United States, 75460

Texas Oncology - Gulf Coast

Recruiting

Pearland, Texas, United States, 77584

Texas Oncology - DFW

Recruiting

Plano, Texas, United States, 75075

Texas Oncology - DFW

Recruiting

Plano, Texas, United States, 75093

Texas Oncology - Gulf Coast

Recruiting

Sugar Land, Texas, United States, 77479

Texas Oncology - Gulf Coast

Recruiting

The Woodlands, Texas, United States, 77380

Texas Oncology - Northeast Texas

Recruiting

Tyler, Texas, United States, 75702

Texas Oncology - Central/South Texas

Recruiting

Waco, Texas, United States, 76712

Texas Oncology - Gulf Coast

Recruiting

Webster, Texas, United States, 77598

Texas Oncology - Central/South Texas

Recruiting

Weslaco, Texas, United States, 78596

Texas Oncology - West Texas

Recruiting

Wichita Falls, Texas, United States, 76310

Huntsman Cancer Institute, University of Utah

Recruiting

Salt Lake City, Utah, United States, 84112

UVA Comprehensive Cancer Center

Recruiting

Charlottesville, Virginia, United States, 22903

UVA Health Fontaine Research Park

Recruiting

Charlottesville, Virginia, United States, 22903

University of Virginia

Recruiting

Charlottesville, Virginia, United States, 22908

UVA Health Cancer Care Pantops

Recruiting

Charlottesville, Virginia, United States, 22911

Northwest Cancer Specialists, P.C.

Recruiting

Vancouver, Washington, United States, 98684

Minnesota Oncology Hematology, P.A.

Recruiting

Hudson, Wisconsin, United States, 54016

Arthur J.E. Child Comprehensive Cancer Centre

Recruiting

Calgary, Alberta, Canada, T2N 5G2

Princess Margaret Cancer Centre - University Health Network

Recruiting

Toronto, Ontario, Canada, M5G 2M9

Windsor Regional Hospital Cancer Program

Recruiting

Windsor, Ontario, Canada, N8W 1L9

Centre Integre universitaire de sante et de services sociaux du Saguenay-Lac-Saint -Jean

Recruiting

Chicoutimi, Quebec, Canada, G7H 5H6

Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre

Recruiting

Greenfield Park, Quebec, Canada, J4V2H1

McGill University Health Centre

Recruiting

Montreal, Quebec, Canada, H4A 3J1

Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎ

Recruiting

Montreal, Quebec, Canada, H4J 1C5

Centre integre universitaire de sante et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke

Recruiting

Sherbrooke, Quebec, Canada, J1H 5N4

More Information

Sponsor

Pfizer

Last update posted

Aug 17, 2026

Last verified

Aug, 2026

Keywords

  • non-squamous NSCLC
  • squamous NSCLC
  • metastatic (Stage IV) squamous or non-squamous NSCLC
  • Advanced or Metastatic Non-Small Cell Lung Cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-13. This information was provided to ClinicalTrials.gov by Pfizer on 2026-08-17.